HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Take the CME quiz: Vol. 29 No. 4, April 2008 Rapid Responses: Submit a response Alert me when this article is cited Alert me when Rapid Responses are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Davis, A. R. Articles by Rosenthal, P. Search for Related Content PubMed PubMed Citation Articles by Davis, A. R. Articles by Rosenthal, P. Related Collections Infectious Diseases Gastrointestinal Disorders

(Pediatrics in Review. 2008;29:111-120.)
© 2008 American Academy of Pediatrics

Hepatitis B in Children

Adam R. Davis, MD^*
Philip Rosenthal, MD

^* Clinical Fellow, Division of Pediatric Gastroenterology, Hepatology and Nutrition, University of California, San Francisco, Calif
Professor of Pediatrics and Surgery; Medical Director, Pediatric Liver Transplant Program; Director, Pediatric Hepatology, University of California, San Francisco, Calif

The first 300 words of the full text of this article appear below.

	Objectives

 
After completing this article, readers should be able to:

1. Describe the structure of the hepatitis B virus and the function of its proteins.
   
2. Delineate the mode of transmission of the virus and identify at-risk populations.
   
3. Interpret the results of screening laboratory tests for hepatitis B.
   
4. Describe the various disease presentations and the natural history and complications of chronic hepatitis B infection.
   
5. List the currently approved therapies for hepatitis B and identify when patients are most likely to benefit from intervention.
   
6. List the current recommendations for immunoprophylaxis in infants, children, and adolescents.
   

	Background

 
One third of the world's population has been infected by the hepatitis B virus (HBV), causing an enormous worldwide burden of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Although the virus can infect people of any age, those who are infected perinatally or as children are at greatest risk for developing the potentially fatal complications of the infection. Approval of the hepatitis B vaccine in 1982 has been the most important development in the clinical approach to this virus, changing the major goal from treatment to prevention. In this article, we review the nature of the virus, its epidemiology, serologic markers of disease, clinical manifestations of infection, the prevention of transmission, and current treatments.

	The Virus

 
HBV is a member of the hepadnavirus family, which is named for its hepatotropic nature and its double DNA genome. It is the only member of the family that causes disease in humans. The virion has two forms: an empty envelope that does not have the potential to infect or replicate and a complete virion. The complete virion is comprised of an envelope containing the capsid, a DNA polymerase, and the viral DNA (Figure). The DNA is 3.2 kilobases long and circular. Hepadnaviruses are unique among DNA viruses in that they are partially double-stranded and . . . [Full Text of this Article]